Revance Therapeutics, Inc.
(NASDAQ GM: RVNC)
Rigrodsky Law, P.A. is investigating Revance Therapeutics, Inc. (“Revance”) regarding possible breaches of fiduciary duties and other violations of law related to Revance’s agreement to be acquired by Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 per share in cash.